Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Muley

Showing results (71-80 of 224) with videos related to

Pageof 23
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2015
Glycodelin: A New Biomarker with Immunomodulatory Functions in Non-Small Cell Lung CancerMarc A Schneider, Martin Granzow, Arne Warth, et al.
British Journal of Cancer|May 31, 2017
Prevalence of somatic mitochondrial mutations and spatial distribution of mitochondria in non-small cell lung cancerDaniel Kazdal, Alexander Harms, Volker Endris, et al.
International Journal of Oncology|February 25, 2022
Transmembrane serine protease 2 is a prognostic factor for lung adenocarcinomaMarc A Schneider, Sarah Richtmann, Anna R Gründing, et al.
Plos One|April 10, 2015
Development and validation of a risk score for predicting death after pneumonectomySeyer Safi, Axel Benner, Janos Walloschek, et al.
Lung Cancer (Amsterdam, Netherlands)|September 30, 2015
The dynamic pattern of recurrence in curatively resected non-small cell lung cancer patients: Experiences at a single institutionYoshikane Yamauchi, Thomas Muley, Seyer Safi, et al.
Radiation Oncology (London, England)|July 6, 2019
Primary adenoid cystic carcinoma of the trachea: clinical outcome of 38 patients after interdisciplinary treatment in a single institutionBenjamin A Högerle, Felix Lasitschka, Thomas Muley, et al.
Anticancer Research|December 27, 2011
The cancer stem cell antigens CD133, BCRP1/ABCG2 and CD117/c-KIT are not associated with prognosis in resected early-stage non-small cell lung cancerEsther Herpel, Katrin Jensen, Thomas Muley, et al.
Respiratory Medicine|March 22, 2014
Characteristics of lung cancer after a previous malignancyNiels Reinmuth, Patrick Stumpf, Andreas Stumpf, et al.
Plos One|January 21, 2017
Prognostic Impact of CT-Quantified Muscle and Fat Distribution before and after First-Line-Chemotherapy in Lung Cancer PatientsJohanna Nattenmüller, Raoul Wochner, Thomas Muley, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|October 16, 2023
Prognostic value of tumor markers ProGRP, NSE and CYFRA 21-1 in patients with small cell lung cancer and chemotherapy-induced remissionThomas Muley, Felix J Herth, Claus Peter Heussel, et al.
Pageof 23

Showing results (71-80 of 224) with videos related to

Sort By:
Pageof 23
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2015
Glycodelin: A New Biomarker with Immunomodulatory Functions in Non-Small Cell Lung CancerMarc A Schneider, Martin Granzow, Arne Warth, et al.
British Journal of Cancer|May 31, 2017
Prevalence of somatic mitochondrial mutations and spatial distribution of mitochondria in non-small cell lung cancerDaniel Kazdal, Alexander Harms, Volker Endris, et al.
International Journal of Oncology|February 25, 2022
Transmembrane serine protease 2 is a prognostic factor for lung adenocarcinomaMarc A Schneider, Sarah Richtmann, Anna R Gründing, et al.
Plos One|April 10, 2015
Development and validation of a risk score for predicting death after pneumonectomySeyer Safi, Axel Benner, Janos Walloschek, et al.
Lung Cancer (Amsterdam, Netherlands)|September 30, 2015
The dynamic pattern of recurrence in curatively resected non-small cell lung cancer patients: Experiences at a single institutionYoshikane Yamauchi, Thomas Muley, Seyer Safi, et al.
Radiation Oncology (London, England)|July 6, 2019
Primary adenoid cystic carcinoma of the trachea: clinical outcome of 38 patients after interdisciplinary treatment in a single institutionBenjamin A Högerle, Felix Lasitschka, Thomas Muley, et al.
Anticancer Research|December 27, 2011
The cancer stem cell antigens CD133, BCRP1/ABCG2 and CD117/c-KIT are not associated with prognosis in resected early-stage non-small cell lung cancerEsther Herpel, Katrin Jensen, Thomas Muley, et al.
Respiratory Medicine|March 22, 2014
Characteristics of lung cancer after a previous malignancyNiels Reinmuth, Patrick Stumpf, Andreas Stumpf, et al.
Plos One|January 21, 2017
Prognostic Impact of CT-Quantified Muscle and Fat Distribution before and after First-Line-Chemotherapy in Lung Cancer PatientsJohanna Nattenmüller, Raoul Wochner, Thomas Muley, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|October 16, 2023
Prognostic value of tumor markers ProGRP, NSE and CYFRA 21-1 in patients with small cell lung cancer and chemotherapy-induced remissionThomas Muley, Felix J Herth, Claus Peter Heussel, et al.
Pageof 23